Athletigen Technologies, a Halifax company dedicated to genetics for athletes, on Monday released its flagship product Iris.

Iris produces human performance insights developed from partnerships with world-class athletes and performance experts. The first of its kind, Iris is a suite of apps that analyzes the athlete’s genetic information. The athletes key in daily monitoring data allowing them

A familiar face on the East Coast startup circuit, Sean Wise had a limited time to answer a range of questions at Invest Atlantic and summed them up in a simple sentence: it’s a great time to be an entrepreneur.

Wise is a professor of entrepreneurship and venture capital at Ryerson University, and served as a consultant to Dragons’ Den when the CBC program was getting off the ground. And he’s

Our Jobs of the Week column this week features an opportunity for a developer interested in working for one of the hottest tech companies in the region.

The Fredericton agriculture technology company Resson, which this year announced it had raised US$11 million (C$14 million) from Monsanto Growth Ventures and other investors, is looking for a Senior User Interface/Front End Developer.

Founded

Cape Breton startups had to compete with Donald Trump, Jeff Hutcheson and Jim Balsillie at the Cape Breton Partnership’s Investor Summit on Thursday, but the young companies more than held their own.

The summit is the annual conference of the organization responsible for economic development on the island. The morning discussions highlighted Balsillie’s purchase and restoration of the Keltic

Pathogens’ growing antibiotic resistance is a global concern. Halifax drug discovery firm Appili Therapeutics Inc. is developing its own solutions, and scouring the world for potential drugs with which to grow the company.

CEO Kevin Sullivan said since Appili formed last year, its strategy has been to balance risk by acquiring drug candidates at different stages of development.

“Our strategy is

As it launches the pilot of its first product, Halifax-based Squiggle Park has been accepted into the Fierce Founders Accelerator, a new program in Kitchener-Waterloo for female tech entrepreneurs.

The Halifax educational technology company, formerly known as EyeRead, is one of nine startups from across the country to be accepted into the new program at Communitech, the ever-expanding innovation

About four years ago, a trio of game developers came together to form a Bedford-based gaming studio called Alpha Dog Games, and quietly began to grow.

The team started with three founders – two of whom, Jeff Cameron and Shawn Woods, are still with the company – and it took on staff as its production increased. In fact, Alpha Dog recently added its 17th employee.

“We have a few big games that

As a former cabinet minister in New Brunswick, Craig Leonard knows how quickly and decisively public opinion develops on social media. It helps him as the CEO of Eyesover, a new Fredericton-based social media monitoring company.

Eyesover is the brainchild of Ali Ghorbani, the dean of the computer science faculty at University of New Brunswick. Over the last decade, he has developed software that

Propel ICT is looking for a few good startups – with the potential of becoming a few great companies.

The regional Atlantic Canadian accelerator is hoping to identify successful startups that would be candidates for the Propel Growth program. This new initiative is designed to help scaling tech companies grow into global corporations.

Propel would like high-growth Atlantic Canadian tech companies with more than $1 million in annual revenue to contact the organization sometime this month. It will then invite the qualifying companies to an information session in early November to outline the

Soricimed Biopharma Inc., the Moncton-based biotech company developing peptide-based cancer treatments, has announced the U.S. Food and Drug Administration has granted orphan drug designation to its flagship compound for the treatment of pancreatic cancer. 

The FDA granted a similar designation earlier this year to the compound SOR-C13 for the treatment of ovarian cancer.

“Receiving orphan drug